Nicolas Trebouta - Onxeo SA Insider

C4X -- Germany Stock  

EUR 1.28  0.00  0.00%

Member of the Board - Permanent Representative of Financiere de la Montagne

Dr. Nicolas Trebouta has served as Member of the Board Permanent Representative of Financiere de la Montagne at Bioalliance Pharma SA as of June 29, 2011. Since 2004, he was via his company Financiere de la Montagne, investing in biotechnology companies, directly or through funds. He cofounded Chevrillon et Associe in 2000 and through this structure achieved several LBO such as Picard, CPI or Alingia . He was a Medical Doctor and shareholder of BioAlliance Pharma SA since 2008. Dr. Trebouta also serves as Manager of SARL Financiere de la Montagne, SCI Fleurus Immobilier and SCI du Trillon Chairman of SAS Dragon 8, and Director of GIE IO, among others.
  Executive Since 2011      
33 1 45 58 76 00  http://www.onxeo.com

Management Efficiency

The company has return on total asset (ROA) of (11.81) % which means that it has lost $11.81 on every $100 spent on asset. This is way below average. Similarly, it shows return on equity (ROE) of (82.07) % meaning that it generated substantial loss on money invested by shareholders.
The company has accumulated 130 K in total debt with debt to equity ratio (D/E) of 0.2 which may suggest the company is not taking enough advantage from borrowing. Onxeo SA has Current Ratio of 1.61 which is within standard range for the sector.

Similar Executives

Entity Summary

Onxeo SA develops drugs for the treatment of orphan oncology diseases worldwide. Onxeo SA was founded in 1997 and is headquartered in Paris, France. Onxeo SA operates under Biotechnology classification in Germany and traded on Frankfurt Stock Exchange. It employs 43 people.Onxeo SA (C4X) is traded on Frankfurt Stock Exchange in Germany. It is located in 49 boulevard du G?n?ral Martial Valin and employs 43 people.

Onxeo SA Leadership Team

Elisabeth Carstensen, Director
Russell Greig, Executive, Ph.D
Remi Droller, Executive
Daniele GuyotCaparros, Executive
Michel Forest, President
Caroline Lemarchand, Director, Ph.D
Olivier Beaumont, Executive, MBA
Aude Michel, Director
Sonia Vallons, Director
Thomas Hofstaetter, Executive
Delphine Lucas, Director
Patrick Langlois, Chairman
Graham Dixon, Executive, Ph.D
Francoise Bono, Executive
Nicolas Trebouta, Executive
Audrey LegentilDumery, Director
Judith Greciet, CEO, Ph.D
Nicolas Fellman, President
David Solomon, Executive, Ph.D
Joseph Zakrzewski, Chairman, MBA
Louis Kayitalire, President, Ph.D
Philippe Maitre, President

Stock Performance Indicators

Did you try this?

Run Premium Stories Now
   

Premium Stories

Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
All  Next Launch Premium Stories

Pair Correlation

Equities Pair Trading Analysis
Correlation analysis and pair trading evaluation for Onxeo SA and Apple. Pair trading can be used as a hedging technique within a particular sector or industry or even over random equities to generate better risk-adjusted return
Run Pair Correlation  
Check also Trending Equities. Please also try Pair Correlation module to compare performance and examine historical correlation between any two equity instruments.